Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Esperion Therapeutics, Inc. | Chief Financial Officer | Common Stock | 82.8K | $103K | $1.25 | Mar 14, 2022 | Direct |
Esperion Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy | 159K | Mar 14, 2022 | Direct | ||
MBX Biosciences, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 42.6K | Sep 12, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MBX | MBX Biosciences, Inc. | Sep 12, 2024 | 1 | $0 | 4 | Sep 13, 2024 | Chief Financial Officer |
MBX | MBX Biosciences, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | Chief Financial Officer |
ESPR | Esperion Therapeutics, Inc. | Mar 14, 2022 | 1 | $0 | 4 | Mar 16, 2022 | Chief Financial Officer |
ESPR | Esperion Therapeutics, Inc. | Oct 29, 2021 | 1 | $0 | 4 | Nov 1, 2021 | Chief Financial Officer |
ESPR | Esperion Therapeutics, Inc. | Jun 28, 2021 | 2 | $0 | 4 | Jun 30, 2021 | Chief Financial Officer |